← Human Trials & Peer-Reviewed Studies
Effect of once-weekly semaglutide versus thrice-daily insulin aspart, both as add-on to metformin and optimized insulin glargine treatment in participants with type 2 diabetes (SUSTAIN 11): A randomized, open-label, multinational, phase 3b trial
Plain-language guide to PMID 35546450 (2022): open-label randomized controlled trial study of Semaglutide and Insulin Glargine in 1748 adults.
Key Facts
- PMID
- 35546450
- Journal
- Diabetes, obesity & metabolism
- Year
- 2022
- Study type
- Randomized Controlled Trial
- Authors
- Kellerer M et al. (7 authors)
- DOI
- 10.1111/dom.14765
- Registered trial
- NCT03689374
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Semaglutide and Insulin Glargine, published as a randomized controlled trial.
Who Took Part
The study group was 1748 adults.
PubMed indexes the participants as adults.
How the Study Was Run
The researchers set it up as a randomized, open-label and parallel-group study.
Because people in this Semaglutide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
Being open-label, the Semaglutide study did not mask who received what.
Groups ran in parallel: each of the adults stayed in one arm throughout.
SUSTAIN 11 (NCT03689374) was a randomized (1:1), parallel, open-label, multinational, phase 3b trial.
The primary outcome was change in HbA1c from randomization to week 52.
Confirmatory secondary endpoints included the occurrence of severe hypoglycaemic episodes and change in body weight (BW).
What Was Measured
Topics PubMed links to this paper include Blood Glucose, Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Glycated Hemoglobin, Hypoglycemia, Hypoglycemic Agents and Insulin Aspart.
Author keywords: GLP-1 analogue, glycaemic control, hypoglycaemia, insulin therapy, type 2 diabetes and weight control.
What This Means in Plain Language
The paper is a randomized, open-label and parallel-group study of Semaglutide and Insulin Glargine in 1748 adults.
With several hundred people or more, it is a fairly large study for this kind of research.
Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2022 (Diabetes, obesity & metabolism), a journal based in England.
More context: the Semaglutide compound page and the Insulin Glargine compound page.
Our Notes on the Compounds
Semaglutide: The active ingredient in several prescription GLP-1 receptor agonist medicines (Ozempic, Wegovy, oral tablets).
Insulin Glargine: A long-acting insulin analog given once daily; brands include Lantus, Toujeo, Basaglar and Semglee.
Insulin Aspart: A rapid-acting mealtime insulin analog; brands include NovoLog, NovoRapid and Fiasp.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.